Division of Hematology/Oncology


faculty photo

Nevena Damjanov, MD

Associate Professor of Clinical Medicine
Attending Physician, Hospital of the University of Pennsylvania
Attending Physician,, Penn Presbyterian Medical Center
Director of GI Oncology, Abramson Cancer Center at the Penn Presbyterian Medical Center
Director, Clinical Research Program, Abramson Cancer Center at the Penn Presbyterian Medical Center
Department: Medicine

Contact information
Penn Presbyterian Medical Center
51 North 39th Street
103A MAB
Philadelphia, PA 19104
Office: 215-662-9154
Fax: 215-243-3249
BA (Biology, Philosophy)
University of Pennsylvania, 1985.
MD (Internal Medicine)
Hahnemann University, 1989.
CTF (Leading Success)
Raymond and Ruth Perelman School of Medicine University of Pennsylvania, 2015.
Post-Graduate Training
Residency in Internal Medicine, M.S. Hershey Medical Center, 1989-1992.
Fellowship in Hematology/Oncology, University of Pennsylvania Medical Center, 1992-1996.
American Board of Internal Medicine (Internal Medicine), 1992.
American Board of Internal Medicine (Medical Oncology), 1995.
American Board of Internal Medicine (Hematology), 1996.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Selected Publications

Mark H. O'Hara, Maryann Gallagher, Ursina R. Teitelbaum, Bruce J. Giantonio, Nevena Damjanov, Arturo Loaiza-Bonilla, Ravi K. Amaravadi, Daniel F Heitjan, Irina Vasilevskaya, Daniel D. Von Hoff, Ramesh K Ramanathan, Dan Laheru, Ana De Jesus-Acosta, Victor E Velculescu, Peter J. O'Dwyer; : Phase 1 trial of gemcitabine/nab-paclitaxel in combination with the autophagy inhibitor hydroxychloroquine in previously untreated patients with metastatic pancreatic adenocarcinoma. J Clin Oncol 33, June 2015.

Arturo Loaiza-Bonilla, Mark H. O'Hara, Maryann Redlinger, Nevena Damjanov, Ursina R. Teitelbaum, Irina Vasilevskaya, Mark Alan Rosen, Daniel F Heitjan, Ravi K. Amaravadi, Peter J. O'Dwyer;: Phase II trial of autophagy inhibition using hydroxychloroquine (HCQ) with FOLFOX/bevacizumab in the first-line treatment of advanced colorectal cancer. J Clin Oncol 33, June 2015.

Mark H. O'Hara, Christine Edmonds, Michael Farwell, Rodolfo F. Perini, Daniel A. Pryma, Ursina R. Teitelbaum, Bruce J. Giantonio, Nevena Damjanov, Priti Lal, Michael D Feldman, Paul J. Zhang, David A. Mankoff, Maryann Gallagher, Angela DeMichele, David J. Vaughn, Peter J. O'Dwyer: Phase II pharmacodynamic trial of palbociclib in patients with KRAS mutant colorectal cancer. J Clin Oncol 33(suppl 3; abstr 626), January 2015.

Lea Lowenfeld MD, Jashodeep Datta MD, Russell S. Lewis Jr., Matthew T. McMillan, Ronac Mamtani MD, Nevena Damjanov MD, Vinay Chandrasakhara MD, Giorgos Karakousis MD, Jeffrey Drebin MD PhD, Douglas Fraker MD, Robert E. Roses MD: Locally Advanced Gastric Cancer: Utilization of Multimodality Approaches and Impact on Survival. Annals of Surgical Oncology 2015 Notes: Accepted for publication.

Divya Yerramilli, Davendra Sohal, Ursina R. Teitelbaum, Paul Stephen Wissel, Nevena Damjanov, Bruce J. Giantonio, Peter J. O'Dwyer, John Peter Plastaras, Edgar Ben-Josef, James M. Metz, John Kucharczuk, Noel Williams, Smith Apisarnthanarax: Adjuvant chemotherapy after trimodality therapy in locally advanced esophageal cancer. J Clin Oncol 32, January 2014.

Sohal DP, Mykulowycz K, Uehara T, Teitelbaum UR, Damjanov N, Giantonio BJ, Carberry M, Wissel P, Jacobs-Small M, O'Dwyer PJ, Sepulveda A, Sun W.: A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma. Ann Oncol 24(12): 3061-5, December 2013.

Sun, W., Sohal, D., Mykulowycz, K., Teitelbaum, U.R., Damjanov, N., Giantonio, B.J., Carberry, M., Wissel, P., Jacobs-Small, M., O’Dwyer, P.J.: An interim evaluation of efficacy and safety of the combination of panitumumab, gemcitabine, and irinotecan in patients with advanced or metastatic cholangiocarcinoma: A phase II study. Journal of Clinical Oncology 30(328a), June 2012 Notes: Poster presentation and abstract.

Davendra Sohal, Ursina R. Teitelbaum, Takeshi Uehara, Kristine Mykulowycz, Christopher D. Watt, Nevena Damjanov, Bruce J. Giantonio, Mary Carberry, Paul Stephen Wissel, Mona Jacobs-Small, Peter J. O'Dwyer, Antonia Sepulveda, Weijing Sun;: A phase II trial of gemcitabine, irinotecan, and panitumumab in advanced cholangiocarcinoma, with correlative analysis of EGFR, KRAS, and BRAF: An interim report. J Clin Oncol 30, June 2012.

Sinha S, Levine M, Damjanov N, Reddy KR, Olthoff K, Shaked A, Hoteit M: Hepato-Cholangiocarcinoma in Liver Transplantation: Frequency and Outcomes. American Journal of Transplantation 11 Suppl 2: 466-466, APR 2011 Notes: Meeting Abstract: 1501 (Poster presentation).

Hall, MJ, Egleston, B, Miller, SM, Buzaglo, JS, Millard, J, Ridgway, C, Damjanov, N, Sprandio, JD, Meropol, NJ: Barriers to participation in cancer prevention clinical trials. Acta Oncologica 49(6): 757-766, AUG 2010.

back to top
Last updated: 07/23/2015
The Trustees of the University of Pennsylvania

Clinical Briefings Blog Spot

Penn MD Forum title with Penn Medicine Shield and Twitter